Prevnar 13

Prevnar 13

vaccine, pneumococcal

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 protein)
Indications/Uses
Active immunization for prevention of invasive disease, pneumonia & acute otitis media caused by Strep pneumoniae in infant & childn from age 6 wk-17 yr & pneumococcal disease (including pneumonia & invasive disease) caused by Strep pneumoniae in adult ≥18 yr.
Dosage/Direction for Use
IM 0.5 mL/dose. Infant 1st dose given at 2 mth, 2nd dose at 4 mth, 3rd dose at 6 mth & 4th dose at 12-15 mth. Previously unvaccinated infant 7-11 mth 2 doses at least 1 mth apart, followed by a 3rd dose after 1 yr from birth, at least 2 mth after the 2nd dose. Previously unvaccinated infant 12-23 mth 2 doses at least 2 mth apart. Previously unvaccinated infant ≥24 mth Single dose. Adult ≥18 yr including those previously vaccinated w/ pneumococcal polysaccharide vaccine Single dose. The need for re-vaccination w/ a subsequent dose has not been established.
Special Precautions
Postpone administrations in patients suffering acute febrile illness. Infants, childn or adults w/ thrombocytopenia or any coagulation disorder or those on anticoagulant therapy.
Adverse Reactions
Inj site erythema, induration/swelling, pain/tenderness, diarrhea, vomiting, fever, decreased appetite, drowsiness, restless sleep, irritability, crying.
ATC Classification
J07AL - Pneumococcal vaccines ; Used for active immunizations.
Presentation/Packing
Form
Prevnar 13 vaccine (inj) 0.5 mL
Packing/Price
(pre-filled syringe) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in